Bristol-Myers Squibb to Expand Massachusetts Biologics Facility

April 11, 2013

Company to Invest Approximately $250 Million, Increase Workforce

(DEVENS, MA, April 11, 2013) – Bristol-Myers Squibb (NYSE: BMY) today announced plans for an approximately $250 million expansion of its large-scale biologics manufacturing facility in Devens, Massachusetts. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.


“Biologics are increasingly important in the treatment of serious diseases and are a growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply. “This initiative is designed to accelerate the development of new biologics medicines through the closer alignment of biologics research and development, and manufacturing.”


Bristol-Myers Squibb plans to construct two new buildings on its 89-acre Devens campus. One will be dedicated to Process Development, a group that designs processes for early production of investigational biologics medicines. A second building will house Clinical Manufacturing, where investigational medicines will be produced to support clinical trials. Both represent new capabilities for Devens, a site that in its early years has focused solely on large-scale, bulk biologics manufacturing.


“This project represents a significant expansion in both the size and mission of Devens,” said Peter Moesta, senior vice president, Biologics Manufacturing and Process Development. “We envision Devens as a center of excellence for the development and manufacture of biologics medicines, optimally organized to support our growing pipeline of investigational medicines and potential new products.”


Together, the two buildings will add approximately 200,000 square feet of laboratory and office space to the Devens site, which is now comprised of six major buildings in a 400,000-square-foot complex.


Construction of the Devens site was completed in 2009. It was Bristol-Myers Squibb’s first major facility in Massachusetts and the largest capital investment in its history – $750 million – and helped signal the company’s transformation into a next-generation biopharmaceutical company. The Devens site also was designed to accommodate future expansion, and the decision to expand reflects both the initial success of Devens and some of the factors that first drew Bristol-Myers Squibb to the region. These include the abundance of biotechnology knowledge, education and training in the Boston area, which has created a large and well-qualified workforce, as well as the inception of the state’s Life Sciences initiative.


Work on the expansion is expected to begin in late 2013 and be completed in 2015. In the interim, Bristol-Myers Squibb has leased 30,000 square feet of laboratory space in nearby Hopkinton, Massachusetts, to begin moving some biologics process development functions closer to Devens during construction. The company intends to maintain this space until construction is completed.

 

Bristol-Myers Squibb Forward Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding plans to expand a biologics manufacturing facility that involves substantial risks and uncertainties. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the expansion of the facility will be completed, or if completed, will be completed on the timeline described in the release. There is also no guarantee that the completion of the expanded facility will receive the required regulatory approvals to accelerate production or that the number of employees expected to be added at the site will be so employed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2012, in our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about the company, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews .


Contact:
John Patella, 732-227-6197, john.patella@bms.com

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.